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Determinants of an elevated pulmonary
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arterial hypertension
Seiichiro Sakao1*, Norbert F. Voelkel2, Nobuhiro Tanabe1 and Koichiro Tatsumi1
Abstract
Given the difficulty of diagnosing early-stage pulmonary arterial hypertension (PAH) due to the lack of signs and
symptoms, and the risk of an open lung biopsy, the precise pathological features of presymptomatic stage lung
tissue remain unknown. It has been suggested that the maximum elevation of the mean pulmonary arterial pressure
(Ppa) is achieved during the early symptomatic stage, indicating that the elevation of the mean Ppa is primarily driven
by the pulmonary vascular tone and/or some degree of pulmonary vascular remodeling completed during this stage.
Recently, the examination of a rat model of severe PAH suggested that the severe PAH may be primarily determined
by the presence of intimal lesions and/or the vascular tone in the early stage. Human data seem to indicate
that intimal lesions are essential for the severely increased pulmonary arterial blood pressure in the late stage
of the disease.
However, many questions remain. For instance, how does the pulmonary hemodynamics change during the
course of the disease, and what drives the development of severe PAH? Although it is generally acknowledged
that both pulmonary vascular remodeling and the vascular tone are important determinants of an elevated pulmonary
arterial pressure, which is the root cause of the time-dependent progression of the disease? Here we review the
recent histopathological concepts of PAH with respect to the progression of the lung vascular disease.
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Introduction
Almost all of the previous large studies which have de-
scribed the features of pulmonary vascular remodeling
in patients with severe angioobliterative PAH, including
IPAH and PAH associated with congenital heart disease
(CHD), have been based on autopsy samples obtained
from patients with end stage PAH [1]. Given the diffi-
culty of diagnosing early-stage PAH because of the lack
of signs and symptoms [2–5], and because we lack open
lung biopsies that are risky in patients with severe PAH,
the pathological features of early lung vascular disease
(during the presymptomatic stage) in patients with severe
PAH remain unclear. Most likely severe angioobliterative
PAH is not histologically homogeneous and the patho-
logical grading method proposed by Heath and Edwards
to assess PAH is based largely on lung tissue samples
from patients with CHD [6]. Heath and Edwards dem-
onstrated that, among PAH patients with CHD, the
medial thickness of the muscular pulmonary arteries
and muscularization of the pulmonary arterioles without
intimal alterations (grade 1) are the earliest abnormalities
of the pulmonary vasculature. These patients were
subjected to high systemic blood pressure from birth
due to congenital cardiac anomalies. Moreover, they
showed that, together with the medial hypertrophy, in-
timal thickness with cell proliferation in the smaller
muscular pulmonary arteries (grade 2), intimal obstruction
with concentric or eccentric masses of less cellular fibrous
tissue (grade 3) and progressive (grade 4) and chronic
(grade 5) dilation of the small arteries with plexiform and
angiomatoid lesions, appear as a result of an elevated
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blood pressure in the pulmonary arteries due to CHD
[6] (Table 1). Although never supported by evidences,
it is generally believed that these pathological alterations
gradually progress over time from grade 1 to 5 [6].
It has also been suggested that the maximum elevation
of the mean pulmonary arterial pressure (Ppa) in PAH
patients is achieved during the early symptomatic stage
[2, 4], indicating that the elevation of the mean Ppa is
driven by the pulmonary vascular tone and/or the degree
of pulmonary vascular remodeling completed during this
stage. The relative contribution of vasoconstriction to
the mean Ppa varies between patients [7] and is perhaps
larger during the presymptomatic phase of PAH due to
the progression of pulmonary vascular remodeling in a
time-dependent manner [6].
Recently, in a rat model of severe PAH it has been
shown that the elevated pulmonary arterial pressure
appears to be primarily driven by grade 1 and 2 remodel-
ing (according to the Heath-Edwards classification) and/or
the vascular tone. Complex vascular lesions, including
those of Heath-Edwards grade 4, may develop as a con-
sequence of the high pulmonary arterial pressure or
shear stress [8, 9].
Here we review the recent histopathological concepts
of PAH with respect to the stage of disease progression,
guided by the questions: how does pulmonary hemodynamics
change during the course of the disease and what de-
gree of pulmonary vascular remodeling increases the
Ppa? We first mention the recent pathophysiological
findings in a rodent model of severe PAH and then the
histopathological features in patients with PAH who
had been treated with the currently available PAH-
targeted drugs. Subsequently, we consider the determi-
nants of the elevated pulmonary arterial pressure from
these findings and the therapeutic strategies in accordance
with different disease stages.
Alterations of the pulmonary hemodynamics
during the course of the disease according with
Heath-Edwards classification: lessons from the
“Sugen/Hypoxia” animal model of pulmonary
hypertension
It has been reported that in a rat model of severe PAH
plexiform-like lesions [8, 10], characteristic of advanced
PAH, develop [11]. This model (the Sugen/Hypoxia
model) is based on a single percutaneous injection in
rats of a vascular endothelial growth factor receptor
blocker (SUGEN5416) which is combined with chronic
exposure to hypoxia for three weeks. As classical rodent
models of mild to moderate pulmonary hypertension
(PH), the chronic hypoxia and monocrotaline models have
been used to investigate the mechanistic basis for the de-
velopment of PH [12]. However, they lack phenotypically
altered proliferated endothelial cells (ECs) in the lumen of
pulmonary arteries and their defining pulmonary vascular
remodeling was medial muscular thickening of proliferat-
ing smooth muscle cells (SMC) [13]. Therefore, there has
been no obvious report focusing on the Heath-Edwards
classification in these rodent models. On the other hand,
in this model, not only plexiform-like lesions, but also
all the pulmonary vascular abnormalities described in
the Heath-Edwards classification, develop in a time-
dependent manner. Importantly there is also a linear
correlation between the right ventricular (RV) systolic
pressure (RVSP) and the number of obliterated vessels
[14]. Remarkably, although the rats in this model de-
velop severe PAH at five weeks after the SUGEN5416
injection, only grade 1 and 2 lesions of the Heath-Edwards
classification were identified at this time point. This
suggests that the severely elevated pulmonary arterial
pressure observed in this rat model is due to these
grade 1 and 2 lesions and/or the vascular tone increase in
the early stage of the disease. The intimal occlusive lesions
gradually progress in this rat model while the degree
of medial thickness is decreasing [15]. These results
suggest that a Heath-Edwards grade greater than 2,
i.e., intimal lesions rather than medial lesions, appear
to be mainly responsible for the increased pulmonary
arterial blood pressure and the increased pulmonary
arterial resistance (PVR) during the later stages of the
disease. More recently de Raaf et al. used telemetry to
monitor the time course of the increase in the RVSP
[9] and found a reversible hypoxic vasoconstriction
component in the Sugen/Hypoxia model and progressive
intima remodeling and a media muscularization that was
in proportion to the chronic hypoxia challenge.
The authors postulated that the hemodynamic and
histological progression in this model are linked, how-
ever it has been critically acknowledged that animal
models may not fully develop the complete spectrum of
human histopathology, particularly when it comes to the
Table 1 The Heath and Edwards pathological grading method
Potenially Reversable
1 The medial thickness of the muscular pulmonary arteries and
muscularization of the pulmonary arterioles without intimal
alterations.
2 Together with the medial hypertrophy, intimal thickness with cell
proliferation in the smaller muscular pulmonary arteries.
3 Intimal obstruction with concentric or eccentric masses of less
cellular fibrous tissue in the arterioles and small muscular arteries.
Large elastic arteries show atherosclerosis.
Usually Irreversible
4 Progressive dilatation of the small arteries with plexiform lesions and
muscle hypertrophy is less apparent.
5 Chronic dilatation of the small arteries with plexiform and
angiomatoid lesions.
6 Necrotizing arteritis with thrombosis.
(Heath D et al., Circulation 1958, 18: 533-547)
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time-dependence of the vascular changes [16]. The
Sugen/Hypoxia rats are kept in a hypoxic chamber for
the first three weeks of the protocol, indicating that
chronic hypoxic pulmonary vasoconstriction (HPV) [17]
likely induces high shear stress [18] and increased gener-
ation and secretion of growth factors and inflammatory
cytokines within and around the pulmonary vasculature.
This is associated with the appearance of smooth muscle-
like cells [19]. In human diseases, however, prolonged
alveolar hypoxia likely occurs only in highlanders with
PH [20] and regionally in patients with respiratory dis-
ease, including chronic obstructive pulmonary disease
(COPD) and pulmonary fibrosis [21]. Taking this fact
into account, the chronic hypoxia PAH model cannot
reproduce the complete human pathobiology. In human
forms of severe PAH phenotypically altered endothelial
cells (ECs) [22, 23], uncontrolled cell proliferation [18, 24],
inflammation [25, 26] and factors which can cause
vasoconstriction or vasodilation [27–29], all appear to have
a role in increasing the pulmonary vascular resistance.
Sequential vascular remodeling according to the
Heath-Edwards classification in human PAH
Stacher and coworkers recently performed a detailed
analysis of the histopathology of explanted lung samples
obtained from 62 PAH patients and 28 control subjects
in order to investigate the potential effects of modern
therapy (prostacyclin and its analogs, phosphodiesterase
type 5 inhibitors and endothelin receptor blockers) on
the histopathological features observed in these patients.
The authors demonstrated that a considerable number
of the explanted lung samples from patients with end-
stage PAH, who had been treated with modern PAH
therapy, exhibited medial thickening that overlapped
with the degree of media thickening found in the control
lungs. On the other hand, they had a similar number
of plexiform lesions as patients with other forms of
progressive PAH [1]. Of the PAH patients 48 were
characterized as a group with an IPAH-like pattern,
which included 27 patients with IPAH, 9 patients with
CHD-PAH, 5 patients with familial PAH, 3 patients
with drug-related PAH, 2 patients with venoocclusive
disease, 1 patient with collagen vascular disease-PAH,
and 1 patient with chronic thromboembolic pulmon-
ary hypertension. There were no significant differences
in the morphometric measurements or the plexiform
lesions between the subgroups.
One particularly important result derived from the
morphometric analysis of the PAH lesions in this study
[1] is that sequential alterations in pulmonary vascular
remodeling, as proposed by Heath and Edwards, may
not be present (or may not occur) in PAH patients
treated with modern therapy. The authors found plexi-
form lesions in the IPAH and associated PAH patients in
spite of unimpressive medial remodeling. A subset of the
explanted lung samples obtained from PAH patients
with a progressive stage of disease had rather unremark-
able medial lesions [1]. This fact supports the finding that
Heath-Edwards classification grades 2 and/or 3 are likely
responsible for the increased pulmonary arterial blood
pressure in the Sugen/Hypoxia model [15]. At the time of
lung transplantation, the intimal lesions with phenotypic-
ally altered mesenchymal-like cells [18, 22, 28, 29], includ-
ing plexiform lesions, rather than medial remodeling,
appeared to determine the elevated Ppa. However, there
was no correlation between the number of plexiform le-
sions and the pulmonary hemodynamic values [1, 30] and
there was only a tendency for a correlation between the
intima plus media fractional thickness and hemodynamic
values [1]. Thus, taken together, this suggests that, if the
degree of occluded and stenosed pulmonary arterioles
may determine the hemodynamics in patients with ad-
vanced PAH, similar to the Sugen/Hypoxia model where
there is a strong correlation between the RVSP and vessel
lumen obliteration [14], the degree of these vascular re-
modeling may not be accurately assessed by either the in-
timal fractional thickness, the intimal volume density or
the number of plexiform lesions.
Alternatively, or additionally still to be identified vaso-
constrictive substances may contribute to the increased
Ppa, even in end stage patients prior to lung transplant-
ation [14]. However, at this stage a thinned and fibrosed
media of the muscular arteries and arterioles appears
[6], making it less likely that severe vasoconstriction
dominates the picture.
If vasoconstriction is prominent, as it must be in those
patients who are treatable with calcium channel blockers,
it is of interest that these patients do not progress. We
postulate that there is likely no pulmonary angiooblitera-
tion. However, histopathological studies of these patients’
lungs are lacking.
Determinants of the elevated pulmonary arterial
pressure
Almost five decades ago, the high pulmonary blood
pressure associated with Heath-Edwards classification
grades 1-3 was shown to be reversible following sur-
gery that primarily eliminated the left to right shunt in
PAH patients with CHD. However, PH associated with
Heath-Edwards classification grade 4 was not reversible, at
least acutely, after surgery [31]. These differences between
grade 3 and 4 are due to the presence of complex in-
timal lesions that are composed of phenotypically altered
mesenchymal-like cells [18, 22, 28, 29], indicating that the
determinants of a fixed high pulmonary arterial pressure
include complex vascular lesions, but not necessarily a
high pulmonary blood flow. Oka et al. investigated the
Sugen/Hypoxia rat model and found that pulmonary
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vascular tone remained to be an important contributing
factor to the high Ppa even in the late stages of the disease.
The role of increased vascular tone, in particular during
exercise and perhaps also controlled by diurnal rhythms,
may be underestimated in patients with fully developed
angioobliterative disease [14] (Fig. 1). As the disease
further progresses, a decrease in the cardiac output due to
right ventricle dysfunction and failure results in a drop in
Ppa while the pulmonary vascular disease is ongoing.
In the Sugen/Hypoxia model, the extent of medial
thickness decreases gradually as the disease progresses,
while the high pulmonary arterial pressure is maintained
[15]. Thus, this finding in the animal model resembles
the data reported by Stacher et al. These authors showed
in their study that approximately 75 % of the lungs in
patients with advanced PAH exhibited a medial frac-
tional thickness which was similar to that in the con-
trols, while 6/28 control lungs had an apparent medial
fractional thickening not associated with plexiform le-
sions or PH [1]. As a reminder, in rodent models of PH
induced by chronic hypoxia or monocrotaline injection,
the medial remodeling and elevated pulmonary arterial
pressure are potentially reversible [13].
Thus, we wonder whether medial remodeling is indeed
the critical factor responsible for the increase in the pul-
monary arterial pressure, or whether the medial wall thick-
ening is to some degree an adaptation of the vasculature to
intermittently higher shear stress. It has been suggested
that PH alters the smooth muscle cells’ (SMCs) fiber
length in order to maintain the transmural pulmonary
arterial pressure as part of the pressure-adapting action
of the pulmonary vasculature [32]. However, in human
idiopathic PAH, the pulmonary arterial SMCs isolated
from these patients showed dysfunctional voltage-sensitive
potassium channels, which participate in pulmonary vas-
cular tone control [33, 34]. It is therefore likely that these
patients’ thickened pulmonary media layers, which are
composed of functionally altered SMCs, have a direct role
in increasing the pulmonary arterial pressure and that the
degree of medial wall thickening is closely related to the
vasoconstrictive potential [30].
Thus, it is likely that both medial and intimal wall re-
modeling contribute to the increase in pulmonary arterial
pressure, as does adventitial remodeling due to proliferat-
ing fibroblasts [35] and deposition of extracellular matrix
(ECM) in the pulmonary arteries [36]. Yet the degree of
vasoconstriction may be limited in vessels altered by
adventitial remodeling and in luminal stenosis (Fig. 1).
Are there therapeutic strategies that are effective
during different disease stages?
The elevated pulmonary arterial pressure appears to
be driven not only by the vascular tone, but also by
the phenotypically altered proliferating cells [24]. The
Fig. 1 The determinants of severe pulmonary hypertension. The determinants of the elevation of the pulmonary arterial pressure in principle
are vasoconstrictive reactivity which may be treatable with currently available vasodilator drugs. Fully developed and endstage disease may be
characterized by complex vascular lesions and vasoconstriction that is refractory to treatment with presently available drugs. Ppa: pulmonary
arterial perssure, PVR: pulmonary vascular resistance
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currently available PH-targeted drugs including pros-
tacyclin and its analogs, phosphodiesterase type 5 in-
hibitors and endothelin receptor blockers play a role
both in opposing any abnormal vasoconstriction and
in inhibiting the growth of SMC [37]. Despite therapy
targeting PH, more than 30 % of PAH patients die
within five years of receiving the diagnosis of severe
PAH [38, 39]. The complex pulmonary vascular lesions
remaining in the explanted lung tissue samples obtained
from drug- treated PAH patients [1, 40] illustrate that the
presently available drugs are not impacting the root causes
of pulmonary vascular remodeling. Very differently, these
drugs are effective in treating the PH in the monocrotaline
rat model [41–44], which is characterized by medial thick-
ening of the pulmonary arteries and muscularization of
the pulmonary arterioles and the lack of intimal complex
vascular lesions, including plexiform lesions [13]. This is
likely attributable to the prominent role of pulmonary
vasoconstriction in this monocrotaline model.
Early diagnosis is conceivably possible in certain forms
of associated PAH (for example in patients with sclero-
derma, HIV/AIDS and sickle cell disease), however, it is
unknown whether early disease stages in these patients
cohorts are dominated by vasoconstriction. Indeed in
patients with systemic sclerosis-associated PAH, the
vascular stiffness caused by luminal stenosis with fi-
brous alterations and medial thickening of arterioles
are prominent histopathological findings throughout
almost all scleroderma disease stages [7]. This implies that
early therapeutic interventions with vasodilator drugs may
not impact the vascular lesions in the PAH patients with
connective tissue disease.
Drugs which can de-remodel the severely altered and
often occluded vessels and novel vasodilators which can
cause vasodilation when the current vasodilator drugs
are not effective are needed for the treatment of patients
with severe PAH.
Conclusion
Longitudinal studies of the Sugen/Hypoxia rat model of
severe PAH have identified early and late disease stages
[8, 9, 14, 15] and recent histopathological studies of lung
explant tissues from patients treated with PH-targeting
drugs have found only a tendency towards a correlation
between the hemodynamic values and the variably rep-
resented pulmonary vascular lesions [1]. Figure 1 pre-
sents the hypothesis that in many, or in some, patients
there may be a presymptomatic, initial disease stage
where pulmonary vasoconstriction may be treatable with
currently available drugs. However, it is not a foregone con-
clusion that early vasodilation treatment would prevent the
progression to vasoobliterative disease. The mechanistic de-
tails of the interplay between hemodynamic pulmonary vas-
cular stress, initial vascular cell apoptosis, subsequent
exuberant cell growth and pulmonary arteriolar lumen ob-
literation remain elusive [24, 45].
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